MENA Pharma Business Development

Online distance learning course. Hence, this course can be accessed online across anywhere 24×7. Moreover, you can attend the course at your convenience in your flexible time. For example, you want to attend the session at your 11 pm at night, you can do that.

1 Year

Any body who wants to acquire drug regulatory affairs competency should attend the course.

Certificate will be provided at the end of the successful completion of the course

Features of Pharma International Business Development & Licensing [MENA region]

• This pharma global management covers all aspects of the strategic management from drug discovery development, regulatory, commercialization, marketing, branding, business development and sales. Hence the course provides
• The course provides orientation to job related practical aspects of the business development managers. Therefore, on completion of the course, the participants will develop the hands on understanding how Business Development Professional works.
• One of the important feature of the course is real life simulation on critical decision making process. Hence, these simulations help to enhance the licensing and  decision making skills which is the core aspects of the pharmaceutical management working.
• Above all the course provides hands on training on drug registration process in each and every MENA countries.

Case Based Learning

• Advance training on strategic management based on the various business regions.
• Course covers regional business development requirements specific to MENA region.
• Access to Case Studies to learn about the drug commercialization steps. Hence, participants will develop advanced competency on strategic portfolio management.

Few of the similar courses

• Middle East Pharma Business Development
• LATAM Business Development
• Medical Devices Global Business Course
• Pharma Strategic Management Course
• Pharma Business Development and Licensing
• US Pharmaceutical and Biopharmaceutical Regulatory Affairs
• Drug Registration and Regulation in China
• Drug Discovery and Development to Commercialization
• European Drug Regulatory Affairs
• Drug Registration and Regulation in GCC countries
• UAE Drug Regulation and Registration
• Drug Registration and Regulation in Saudi Arabia
• Middle East Drug Regulatory Affairs

MENA Pharma Market – Overview

The MENA (Middle East and North Africa) pharma market is a rapidly growing market, with a current estimated value of approximately $60 billion USD. The market is expected to continue growing, driven by factors such as an increasing demand for healthcare services, rising populations, and the prevalence of chronic diseases.

Some of the largest markets within the MENA region include Saudi Arabia, Iran, and Egypt. However, other countries such as the UAE, Turkey, and Morocco are also experiencing significant growth in their pharmaceutical sectors.

Countries in MENA

The MENA region is also characterized by a large number of domestic pharmaceutical manufacturers, as well as a growing number of multinational companies that are expanding their presence in the region. Governments within the region have also taken steps to encourage the growth of the pharma sector, such as through the implementation of regulatory frameworks and investment in healthcare infrastructure.

The market is dominated by generic drugs, which make up over 70% of total pharmaceutical sales in the region. However, there is an increasing demand for innovative and specialty drugs, particularly in the areas of oncology, immunology, and rare diseases.

Some of the major multinational pharmaceutical companies, including Pfizer, Sanofi, and Novartis, have a strong presence in the MENA region. Local pharmaceutical companies are also emerging and expanding, particularly in countries such as Egypt, Saudi Arabia, and the United Arab Emirates.

The MENA pharmaceutical market faces some challenges, such as regulatory barriers, intellectual property protection, and pricing pressures. However, the market presents significant growth opportunities, driven by increasing healthcare spending, a growing population, and an increasing demand for innovative and specialty drugs.